Tudor Investment Corp ET AL Buys 116,803 Shares of Cryoport, Inc. (NASDAQ:CYRX)

Tudor Investment Corp ET AL raised its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 271.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 159,779 shares of the company's stock after purchasing an additional 116,803 shares during the period. Tudor Investment Corp ET AL owned 0.32% of Cryoport worth $1,243,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CYRX. Avanza Fonder AB purchased a new position in shares of Cryoport during the 4th quarter worth approximately $64,000. Quarry LP purchased a new position in shares of Cryoport during the 4th quarter worth approximately $69,000. Nebula Research & Development LLC grew its holdings in shares of Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after acquiring an additional 2,207 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Cryoport by 135.5% during the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company's stock worth $100,000 after acquiring an additional 7,407 shares during the period. Finally, Olympiad Research LP purchased a new position in shares of Cryoport during the 4th quarter worth approximately $103,000. Institutional investors own 92.90% of the company's stock.

Insider Activity

In related news, CEO Jerrell Shelton sold 4,620 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the transaction, the chief executive officer now directly owns 765,399 shares of the company's stock, valued at approximately $4,814,359.71. This trade represents a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 19,830 shares of company stock valued at $118,353 in the last ninety days. 10.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on CYRX. UBS Group upped their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Morgan Stanley cut their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Roth Mkm restated a "buy" rating and issued a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Needham & Company LLC restated a "buy" rating and issued a $11.00 price target on shares of Cryoport in a research note on Thursday. Finally, Guggenheim restated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a research note on Wednesday, April 16th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.00.

Cryoport Stock Up 1.3%

CYRX stock traded up $0.09 during midday trading on Friday, hitting $7.07. The company's stock had a trading volume of 549,895 shares, compared to its average volume of 541,988. The company has a market cap of $354.47 million, a PE ratio of -2.09 and a beta of 1.92. Cryoport, Inc. has a 12 month low of $4.58 and a 12 month high of $14.21. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm's 50-day moving average is $5.88 and its 200-day moving average is $6.86.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. On average, equities research analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.